Evidence map›Paper›PMID 33490224›Full record

ReviewAnnals of translational medicine2020

Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.

Eleftherios P Samartzis, S Intidhar Labidi-Galy, Michele Moschetta, Mario Uccello, Dimitrios R Kalaitzopoulos, J Alejandro Perez-Fidalgo, Stergios Boussios

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Eleftherios P SamartzisDepartment of Gynecology and Gynecological Cancer Center, University Hospital Zurich, Zurich, Switzerland.
S Intidhar Labidi-GalyDepartment of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Michele MoschettaCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mario UccelloNorthampton General Hospital NHS Trust, Cliftonville, Northampton, UK.
Dimitrios R KalaitzopoulosDepartment of Gynecology and Gynecological Cancer Center, University Hospital Zurich, Zurich, Switzerland.
J Alejandro Perez-FidalgoDepartment of Medical Oncology, Hospital Clinico Universitario de Valencia, INCLIVA, CIBERONC, Valencia, Spain.
Stergios BoussiosDepartment of Medical Oncology, Medway NHS Foundation Trust, Gillingham, Kent, UK.
University Hospital of Zurich · CHCambridge University Hospitals NHS Foundation Trust · GBCentro de Investigación Biomédica en Red de Cáncer · ESHôpital Beau-Séjour · CHMedway NHS Foundation Trust · GBNorthampton General Hospital NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometriosis is a benign gynecologic condition affecting up to one woman out of ten of reproductive age. It is defined by the presence of endometrial-like tissue in localizations outside of the uterine cavity. It often causes symptoms such as chronic pain, most frequently associated with the menstrual cycle, and infertility, but may also be oligo- or asymptomatic. There is evidence that some ovarian carcinoma (OC) histotypes, mainly the ovarian clear cell (OCCC) and endometrioid (EnOC) carcinoma, may arise from endometriosis. The most frequent genomic alterations in these carcinomas are mutations in the AT-rich interacting domain containing protein 1A (

Indexed as

ARID1A mutationsclear cell ovarian carcinomaendometrioid ovarian carcinomaendometriosisOvarian cancerPI3K/AKT/mTor pathwaySWI/SNF transcription complexsynthetic lethalitytreatment

Identifiers

PMID33490224
PMCPMC7812165
OpenAlexW3113488259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.